EUVIMEDEUVIMED entdecken
Crossref

Dermatomyositis in Association With SARS‐CoV ‐2 Infection or COVID ‐19 Vaccine

Maximiliano Diaz-Menindez iD, Megan M Sullivan iD, Benjamin Wang, Vikas Majithia, Andy Abril, Ronald R Butendieck, Colleen T Ball, Florentina Berianu

Arthritis Care & Research · 2024

DOI: 10.1002/acr.25236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Maximiliano Diaz-Menindez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Scottsdale, Arizona. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Dermatomyositis, Myositis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

New‐onset and relapsed dermatomyositis (DM) has been reported following SARS‐CoV‐2 infection or COVID‐19 vaccination. This study aims to show the characteristics of a DM cohort after COVID‐19 infection and vaccination.

Methods

A retrospective review was performed on patients treated for DM between March 1, 2020, and October 31, 2022. Charts were evaluated for the presence of new‐onset DM or relapse of preexisting DM following either SARS‐CoV‐2 infection or COVID‐19 vaccination. Data on symptom onset, timing of vaccination, type of vaccination, and disease characteristics were collected.

Results

Ninety‐eight patients treated for DM at our institution in the Division of Rheumatology were included. In total, 12 of 98 patients (12.2%) experienced DM symptoms (either incident or relapse) following either infection or vaccination. Of the 12 patients who developed incident disease or relapse, 7 (58.3%) developed postinfection symptoms, and 8 (66.7%) developed symptoms after vaccination (3 patients had symptoms following both infection and vaccination). The mean onset of symptoms following COVID‐19 infection was 3.2 days (median 0.5 days), and mean onset following COVID‐19 vaccination was 5.75 days (median 3.5 days). Nine of 12 patients (75%) had a positive myositis‐specific antibody, and the remaining 3 (25%) had myositis‐associated antibodies. There was no predominant vaccine associated with the development of postvaccination DM symptoms.

Conclusion

This retrospective review revealed a strong temporal relationship between DM symptoms and COVID‐19 infection or vaccination in 12.2% of all patients with DM evaluated in our clinic during the pandemic. Additional studies are required to understand the possible pathophysiology behind this association.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesDermatomyositisMyositisHumansRecurrenceSARS-CoV-2Vaccination

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Mayo Clinic, Scottsdale, Arizona.
  • Mayo Clinic, Jacksonville, Florida.

ORCID-Profile: Maximiliano Diaz-Menindez, Megan M Sullivan

Zitieren

APA

Diaz-Menindez, M., Sullivan, M. M., Wang, B., Majithia, V., Abril, A., Butendieck, R. R., Ball, C. T., & Berianu, F. (2024). Dermatomyositis in Association With SARS‐CoV ‐2 Infection or COVID ‐19 Vaccine. Arthritis Care & Research. https://doi.org/10.1002/acr.25236

Vancouver

Diaz-Menindez M, Sullivan MM, Wang B, Majithia V, Abril A, Butendieck RR, et al. Dermatomyositis in Association With SARS‐CoV ‐2 Infection or COVID ‐19 Vaccine. Arthritis Care & Research. 2024. doi:10.1002/acr.25236

BibTeX
@article{DiazMenindez2024,
  author = {Diaz-Menindez, Maximiliano and Sullivan, Megan M and Wang, Benjamin and Majithia, Vikas and Abril, Andy and Butendieck, Ronald R and Ball, Colleen T and Berianu, Florentina},
  title = {Dermatomyositis in Association With SARS‐CoV ‐2 Infection or COVID ‐19 Vaccine},
  journal = {Arthritis Care & Research},
  year = {2024},
  doi = {10.1002/acr.25236}
}
Kostenlos starten →